問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許哲維

Recruiting

List

9Cases

2021-01-01 - 2029-07-31

Phase III

Active
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis

  • Condition/Disease

    Myasthenia Gravis

  • Test Drug

    Inebilizumab

Participate Sites
8Sites

Recruiting4Sites

Terminated4Sites

2022-06-15 - 2029-09-30

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-07-14 - 2027-04-17

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-11-01 - 2029-03-18

Phase III

Active
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis

  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    注射液 注射液

Participate Sites
5Sites

Recruiting5Sites

2023-01-01 - 2027-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis

  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-09-01 - 2024-05-31

Phase III

A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.

  • Condition/Disease

    Relapsing Multiple Sclerosis

  • Test Drug

    Evobrutinib

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated1Sites

郭育呈
China Medical University Hospital

Division of Neurology

2021-11-01 - 2027-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-02-01 - 2021-09-15

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis.

  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Recruiting5Sites

郭育呈
China Medical University Hospital

Division of Neurology

2021-02-03 - 2024-01-25

Phase III

An open-label extension study to evaluate rozanolixizumab in study participants with generalized myasthenia gravis

  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting1Sites

Study ended1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB